Enrolling Studies

The research team at ARC is currently managing several different clinical studies. Are you interested in a particular study opportunity? Information about current study opportunities currently enrolling patients can be found below. Both ARC patients and non-ARC patients who fit the trial eligibility requirements are welcome.

• BaxDuo Arctic Chronic Kidney Disease (CKD) Clinical Study

  A phase III, randomized, double-blind, active-controlled study intended to assess the efficacy, safety, and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease (CKD) progression in participants with CKD and high blood pressure.

  About the Study

• Clinical Biospecimen Collection for Alzheimer's and Parkinson's Disease Biomarker Research

  Biospecimen collection for subjects with clinically established Alzheimer's or Parkinson's Disease to support biomarker research. Must be willing to undergo a 1-time blood draw and urine collection.

  About the Study

• Credo SARS-CoV-2, Flu, and RSV Clinical Study

  Clinical performance evaluation of the VitaSIRO solo™ SARSCoV-2/Flu/RSV Assay.

  About the Study

• DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study

  Enrollment into the study will occur after informed consent and eligibility is confirmed. After enrollment, blood specimens (~40 mL) will be collected and a medical record review will be completed 12 months post-enrollment. Medical history, demographics, diagnostic reports, surgery reports, imaging reports, pathology reports, and/or other diagnostic information will also be collected.

  About the Study

• ENABLE Multiple Sclerosis (MS) Clinical Study

  A long-term observational registry study for patients with multiple sclerosis (MS) to collect real-world data on BRIUMVI (infusion medication) and assess efficacy, safety, and tolerability of medication.

  About the Study

• SQNM COVID-19, Flu, and RSV Swab Sample Study

  The SQNM swab study is collecting swab samples from patients experiencing symptoms of flu A, flu B, RSV, and/or COVID-19, which will support the development of a test to detect these viruses.

  About the Study

• Trailblazer Alzheimer’s Disease Study

  A long-term, real-world study comparing the effectiveness of Donanemab along with usual care to usual care alone in U.S. patients with early symptomatic Alzheimer’s Disease.

  About the Study